These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22572805)

  • 21. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
    Nozawa M; Inagaki T; Nagao K; Nishioka T; Komura T; Esa A; Kitagawa M; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uejima S; Matsuyama H; Hara I; Uemura H
    Int J Clin Oncol; 2014 Aug; 19(4):693-701. PubMed ID: 23912936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
    Rosen L; Harland SJ; Oosterlinck W
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S19-24. PubMed ID: 12562047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
    Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
    Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
    Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
    Cameron D
    Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A; Zheng M; Seaman J
    Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
    Lipton A
    Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    Major PP; Cook R
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.